R&D and Innovation
- Time of issue:2021-05-24 10:36:47
Zhuhai Livzon Bio-Pharmaceutical Technology Co., Ltd.
Zhuhai Livzon Bio-Pharmaceutical Technology Co., Ltd. ("Livzon Bio", a foreign-invested, non-wholly-owned enterprise) is a high-tech enterprise founded by Livzon Group and Joincare, focusing on the development of innovative drugs for the world's leading macromolecules. The core business entity was established in July 2010, headquartered in Jinwan District, Zhuhai City, with a registered capital of RMB 1.45333 billion. The main business is independent innovation research and development and industrialization of biological drugs, including innovative monoclonal antibodies, monoclonal antibody-like drugs, Bispecific antibodies, antibody-conjugated drugs, CAR-T cell therapy, etc. The products cover tumors, autoimmune diseases and other fields. They are an important part of the innovation capacity building project of Livzon Pharmaceutical Group's national enterprise technology center (antibody drug experiment Room), is a unicorn enterprise in Zhuhai in 2018, and a new research and development institution in Zhuhai in 2015 and 2018.
In the Livzon Industrial Park, Livzon Bio has established a typical demonstration base for the industrialization of antibody drugs in Guangdong Province, with a construction area of nearly 20,000 square meters. It has established a range of antibody humanization, cell line screening, large-scale cell culture, purification, preparation, and analysis. An integrated technology platform for testing and quality control, with GE disposable reactor production lines consisting of 2 sets of 200L, 1 set of 500L and 1 set of 2000L disposable reactors, and 1 set of 500L and 1 set of 1500L stainless steel reactors from ABEC The stainless steel reactor production line is fully equipped with the conditions for the research and development and industrialization of antibody drugs.
There are currently 15 projects under research, including 1 new drug product completed application (BLA), 9 new drugs are in the clinical research stage, 1 new drug has been approved by the FDA for clinical research in the United States; 2 of these projects have been nationally major new drug creation. Intellectual property rights: 30 invention patents have been applied for, and 23 patents have been authorized. Livzon Bio currently employs nearly 280 people, including 15 doctors, accounting for 71.58% of the bachelor degree or above. It has won the third batch of innovative scientific research teams introduced by Guangdong Province, the key overseas Chinese entrepreneurship team of the Overseas Chinese Affairs Office of the State Council, and the honorary titles of Zhuhai innovative scientific research team.